Human CCR2 Virus-Like Particles

Human C-C chemokine receptor type 2 (CCR2) is a G protein-coupled receptor (GPCR) primarily expressed on immune cells, including monocytes, macrophages, and dendritic cells. It plays a key role in mediating inflammatory responses by binding to chemokines such as CCL2 (MCP-1), CCL7, and CCL8. CCR2 plays a crucial role in recruiting monocytes to sites of inflammation, infection, or injury, making it a key player in diseases such as atherosclerosis, rheumatoid arthritis, and cancer metastasis. Due to its central role in immune cell migration, CCR2 has emerged as a promising therapeutic target for modulating inflammatory and autoimmune diseases.

To overcome these challenges, CCR2 virus-like particles (VLPs) have been developed as a powerful research tool with potential therapeutic applications. VLPs are non-infectious, self-assembling nanostructures that mimic the structure of native viruses but do not contain viral genetic material. By incorporating CCR2 into VLPs, researchers can present the receptor in a membrane-bound, biologically relevant conformation while maintaining stability and ease of purification. CCR2-VLPs retain the receptor''s ability to bind chemokines and interact with downstream signaling molecules, making them ideal for drug screening, antibody development, and structural studies. Compared to traditional soluble or recombinant CCR2, VLPs better mimic the native cellular environment, bridging the gap between in vitro assays and in vivo conditions.